Frontlight ResearchEarly access
Taking peoplePhase 1/2
A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Participants With Pi*ZZ AATD
Key facts
- Who runs it
- Wave Life Sciences USA, Inc.
- Where
- Australia, Canada, Finland, Germany, New Zealand, and United Kingdom9 sites in 6 countriesChoose a country to see its sites
- Trial code
- NCT06405633
- EU 2024-511981-36-00
- U1111-1311-8996
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 48 people, planned
- Started
- 19 Jul 2024
- Expected to end
- Sept 2027
- Type of study
- Interventional, 5 groups
- Treatments tested
- WVE-006
- Record updated
- 16 November 2026
Who can take part
- Age
- 18 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Healthy as determined by the Investigator, based on a medical evaluation, or has mild to moderate AATD-induced lung disease (FEV1 ≥50%) and/or stable mild AATD-induced liver disease (≤F2 (≤10 kPa) on FibroScan
- Genetic testing confirming Pi*ZZ
- Participant has been a non-smoker for at least 1 year prior to screening
Who cannot take part
- • Participant has a history of multiple drug allergies or of allergic reaction to an oligonucleotide or to N-acetylgalactosamine (GalNAc); Participant has a history of intolerance or any medical condition that might interfere with subcutaneous injections; Any ongoing or recent infections; Any recent or planned vaccinations during the study; Participant has a history of regular alcohol consumption exceeding 14 standard drinks/week; Unwilling to abstain from alcohol for 48 hours prior to dosing at each of the dosing visits; Any recent or planned major surgery during the study; Participant has any medical condition or social circumstance that, in the opinion of the Investigator, would make the participant unsuitable for participation in the study or for dosing on Day 1, or could interfere with the assessments of safety, pharmacodynamics, or pharmacokinetics, or completion of the study; Participant currently on AAT augmentation therapy, planned to be on augmentation therapy anytime during the study, or has been on augmentation therapy within 30 days prior to Screening Visit; Donation of blood or blood products in excess of 500 mL within 12 weeks prior to Screening Visit and/or unwilling to refrain from blood donation for the duration of the study; Participant has received an investigational agent within 3 months of the Screening Visit
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
This trial has no sites in United States.
It has sites in 6 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of this open-label study is to assess the safety, tolerability, pharmacodynamics, and pharmacokinetics of WVE-006 in participants with alpha-1 antitrypsin deficiency (AATD) following Period 1 single ascending dose (SAD) and Period 2 multiple ascending doses (MAD), respectively.
The 5 groups in the trial
- WVE-006 (Dose 1)Treatment being tested
Treatment: WVE-006
- WVE-006 (Dose 2)Treatment being tested
Treatment: WVE-006
- WVE-006 (Dose 3)Treatment being tested
Treatment: WVE-006
- WVE-006 (Dose 4)Treatment being tested
Treatment: WVE-006
- WVE-006 (Dose 5)Treatment being tested
Treatment: WVE-006
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Phase 1b/2a Open-label Single Ascending Doses (SAD) and Multiple Ascending Doses (MAD) Research Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Participants With AATD Pi*ZZ on WVE-006 (RestorAATion-2)
- Criteria questions
- Built from NCT06405633, who can take part
- Record updated
- 16 November 2026